Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Quote. Delayed Nasdaq - 10/30 04:00:00 pm
58.15 USD   -0.65%
10/29GLOBAL MARKETS LIVE: Big names today
10/29GILEAD SCIENCES : Announces Fourth Quarter 2020 Dividend
AQ
10/29GILEAD SCIENCES : Announces Third Quarter 2020 Financial Results
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at USD 55.15 USD in weekly data.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • With an enterprise value anticipated at 3.91 times the sales for the current fiscal year, the company turns out to be overvalued.
  • With an expected P/E ratio at 107.07 and 10.27 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the past seven days, analysts have been lowering their EPS expectations for the company.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The underlying tendency is negative on the weekly chart below the resistance at 69.36 USD
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
GILEAD SCIENCES, INC.-10.51%72 904
REGENERON PHARMACEUTICALS44.76%57 199
VERTEX PHARMACEUTICALS-4.84%54 210
WUXI APPTEC CO., LTD.71.31%40 863
BEIGENE, LTD.78.89%26 872
GENMAB A/S43.71%21 783
BIONTECH SE151.95%20 330
HUALAN BIOLOGICAL ENGINEERI..89.36%13 962
MYOKARDIA, INC.206.69%11 919
-
ARGENX SE49.30%11 829
SAREPTA THERAPEUTICS, INC.5.34%10 671
MIRATI THERAPEUTICS, INC.68.51%10 584
NEUROCRINE BIOSCIENCES, INC..-8.21%9 201
ASCENDIS PHARMA A/S17.42%8 691
ULTRAGENYX PHARMACEUTICAL I..135.31%6 582
BIOCON LIMITED37.42%6 415
More Results
Financials (USD)
Sales 2020 23 690 M - -
Net income 2020 424 M - -
Net Debt 2020 19 768 M - -
P/E ratio 2020 107x
Yield 2020 4,63%
Capitalization 72 904 M 72 904 M -
EV / Sales 2020 3,91x
EV / Sales 2021 3,66x
Nbr of Employees 11 800
Free-Float 99,7%
Upcoming event on GILEAD SCIENCES, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes